+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Patient-Derived Xenograft/PDX Model Market - Global Forecast 2026-2032- Product Image
Patient-Derived Xenograft/PDX Model Market - Global Forecast 2026-2032- Product Image
New

Patient-Derived Xenograft/PDX Model Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5637019
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Patient-derived xenograft (PDX) models are reshaping how oncology leaders approach translational research, offering a high-fidelity platform that bridges laboratory discoveries and clinical development. As global demand grows for preclinical predictability and robust therapeutic validation, this market’s evolution remains top-of-mind for senior decision-makers.

Market Snapshot: Patient-Derived Xenograft/PDX Model Market

The Patient-Derived Xenograft/PDX Model Market expanded from USD 597.44 million in 2025 to USD 678.51 million in 2026 and is projected to sustain a compound annual growth rate of 15.02%, achieving USD 1.59 billion by 2032. This growth underscores increasing adoption by pharmaceutical companies, academic research centers, and biotechnology developers seeking more representative models for cancer research and drug development.

Scope & Segmentation of the Patient-Derived Xenograft/PDX Model Market

This report delivers granular analysis of how the PDX model market is segmented and the operational priorities shaping its deployment:

  • Model Types: Includes mouse and rat models, each optimized for particular study endpoints, tumor growth rates, and engraftment efficiencies.
  • Tumor Origins: Covers gastrointestinal, gynecological, hematological, respiratory, and urological cancers, providing tailored research avenues for variable microenvironmental factors and therapeutic responses.
  • Study Modalities: Encompasses ex-vivo, in-vitro, and in-vivo applications, supporting diverse research designs from direct tumor interrogation to systemic pharmacokinetic studies.
  • Implantation Techniques: Features heterotopic, orthotopic, and subcutaneous approaches to address different growth patterns, metastatic propensities, and microenvironment fidelities.
  • Application Focus: Involves segments such as basic cancer biology, drug efficacy evaluation, biomarker discovery, genomic profiling, tumor microenvironment research, and personalized medicine efforts.
  • End-User Needs: Accommodates research institutes, cancer centers, pharmaceutical companies, and biotechnology organizations, each balancing requirements for customization, scalability, and reproducibility.
  • Regional Coverage: Analyzes trends and infrastructure across the Americas, Europe, Middle East & Africa, and Asia-Pacific, examining how regulatory environments, collaboration models, and local capacities influence study execution.
  • Enabling Technologies: Includes advancements in multi-omics profiling, humanized host systems, high-resolution imaging, and standardized digital platforms to maximize model fidelity and workflow integration.

Key Takeaways for Strategic Decision-Makers

  • Pooled clinical specimens in PDX models preserve tumor diversity and genomic complexity, driving improved preclinical predictability for candidate therapies.
  • Standardization of engraftment protocols and annotation practices supports reproducibility, comparability, and streamlined cross-institutional collaborations.
  • Growth in humanized host models and advanced molecular workflows expands research scope into immuno-oncology and enables more granular therapeutic insights.
  • Operational shifts toward integrated translational pipelines combine PDX data with organoids, in vitro systems, and computational analyses to balance throughput and fidelity.
  • Segment granularity—from model selection to end-user priorities—determines experimental fit and streamlines paths to clinical validation.
  • Regional ecosystem factors, such as research infrastructure and regulatory alignment, shape collaboration patterns and optimize implementation strategies.

Tariff Impact on Patient-Derived Xenograft/PDX Model Market

Recent changes in United States tariff policy have redefined the supply chain matrix for the PDX sector. These policies affect reagent costs, cross-border specimen transfers, and global collaboration logistics. Organizations are adapting by diversifying suppliers, building domestic partnerships, and localizing manufacturing when possible. Tariff-induced pressures have also prompted investments in procurement agility and process redesign to ensure continuity in research workflows.

Methodology & Data Sources

The research integrates structured expert interviews, protocol audits, and systematic literature reviews to ensure a comprehensive and nuanced analysis. Data triangulation connects operational evidence with peer-reviewed findings, emphasizing analytical rigor and reproducibility while accounting for the dynamic evolution of PDX methodologies.

Why This Report Matters

  • Enables informed decision-making by clarifying segmentation, operational strategies, and technology adoption trends in the patient-derived xenograft model market.
  • Highlights actionable best practices for sourcing, quality assurance, and cross-platform data integration in translational oncology.
  • Offers regional insights that inform partnership strategies, regulatory navigation, and resource allocation for global implementation.

Conclusion

Robust patient-derived xenograft models provide a critical bridge between laboratory research and oncology innovation. Strategic alignment across segmentation, operational resilience, and collaborative best practices empowers stakeholders to translate preclinical evidence into meaningful clinical outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Patient-Derived Xenograft/PDX Model Market, by Type
8.1. Mice Models
8.2. Rat Models
9. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
9.1. Gastrointestinal
9.2. Gynecological
9.3. Hematological
9.4. Respiratory
9.5. Urological
10. Patient-Derived Xenograft/PDX Model Market, by Study Type
10.1. Ex-vivo
10.2. In-vitro
10.3. In-vivo
11. Patient-Derived Xenograft/PDX Model Market, by Implantation Method
11.1. Heterotopic
11.2. Orthotopic
11.3. Subcutaneous
12. Patient-Derived Xenograft/PDX Model Market, by Application
12.1. Basic Cancer Research
12.2. Biomarker Discovery
12.3. Genomic & Molecular Studies
12.4. Personalized Medicine
12.5. Preclinical Drug Evaluation
12.6. Tumor Microenvironment Analysis
13. Patient-Derived Xenograft/PDX Model Market, by End-User
13.1. Academic Research Institutes
13.2. Cancer Research Centers
13.3. Pharmaceutical & Biotechnology Companies
14. Patient-Derived Xenograft/PDX Model Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Patient-Derived Xenograft/PDX Model Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Patient-Derived Xenograft/PDX Model Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Patient-Derived Xenograft/PDX Model Market
18. China Patient-Derived Xenograft/PDX Model Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Abnova Corporation
19.6. Altogen Labs
19.7. Biocytogen
19.8. BioDuro LLC
19.9. BioReperia AB
19.10. Certis Oncology Solutions
19.11. Champions Oncology, Inc.
19.12. Charles River Laboratories International, Inc.
19.13. Creative Animodel
19.14. Creative Biolabs
19.15. Crown Bioscience by JSR Corporation
19.16. EPO Berlin-Buch GmbH
19.17. GemPharmatech Co. Ltd.
19.18. Genesis Drug Discovery & Development
19.19. Hera Biolabs
19.20. HOIST Co.,Ltd.
19.21. InnoSer
19.22. Inotiv, Inc.
19.23. Laboratory Corporation of America Holdings
19.24. LIDE Shanghai Biotech, Ltd
19.25. Mediford Corporation by PHC Holdings Corporation
19.26. Oncodesign Services
19.27. Shanghai ChemPartner
19.28. Shanghai Medicilon Inc.
19.29. TheraIndx Lifesciences Pvt. Ltd.
19.30. Urosphere SAS
19.31. WuXi AppTec Co., Ltd.
19.32. Xentech
List of Figures
FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 105. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 106. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 108. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 117. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 119. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 120. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 121. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 122. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 134. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 135. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 136. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 137. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 138. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 139. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 141. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 142. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 143. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 144. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 153. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 155. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 156. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 157. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 158. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 160. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 162. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 163. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 164. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 165. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 166. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 167. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 169. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 170. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 171. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 172. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 182. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 183. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 184. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
TABLE 185. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
TABLE 186. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
TABLE 187. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 188. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Patient-Derived Xenograft/PDX Model market report include:
  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai Biotech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 678.51 Million
Forecasted Market Value ( USD ) by 2032 $ 1590 Million
Compound Annual Growth Rate15.0%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Patient Derived Xenograft (PDX) Models Market Report 2025 - Product Image

Patient Derived Xenograft (PDX) Models Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030 - Product Image

Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030

  • Report
  • 367 Pages
  • Global
From
Patient Derived Xenograft / PDX Models - Global Strategic Business Report - Product Image

Patient Derived Xenograft / PDX Models - Global Strategic Business Report

  • Report
  • 310 Pages
  • Global
From
Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report 2025 - Product Image

Oncology Based in-Vivo CRO Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Patient Derived Xenograft Market

The Patient Derived Xenograft (PDX) market is a rapidly growing segment of the drug discovery industry. PDX models are derived from human tumors that are implanted into immunodeficient mice, allowing researchers to study the effects of drugs on human cancer in a living system. PDX models are used to identify new drug targets, evaluate drug efficacy, and assess drug safety. They are also used to study the biology of cancer and to develop personalized treatments. PDX models are increasingly being used in clinical trials to evaluate the efficacy of new drugs. PDX models offer several advantages over traditional cell-based models, including the ability to study the effects of drugs on a living system, the ability to study the effects of drugs on multiple tumor types, and the ability to study the effects of drugs on the tumor microenvironment. Companies in the PDX market include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and Taconic Biosciences. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.